Skip to main content

Mallinckrodt Pharmaceuticals Value Stock - Dividend - Research Selection

Mallinckrodt

ISIN: IE00BBGT3753 , WKN: A1W0TN

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products. It offers H.P. Acthar Gel, an injectable drug for various indications, such as proteinuria, multiple sclerosis, infantile spasms, ophthalmic, neuromuscular disorders, dermatomyositis, polymyositis, rheumatology, and pulmonology; Inomax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Ofirmev, an intravenous formulation of acetaminophen for pain management; Therakos, an immunotherapy treatment platform; and Amitiza for the treatment of chronic idiopathic constipation. The company is also developing StrataGraft, which is in Phase III and II clinical development for the treatment of burns; terlipressin for the treatment of hepatorenal syndrome; MNK-1411 for the treatment of Duchenne muscular dystrophy; Stannsoporfin, a heme oxygenase inhibitor for the treatment of jaundice; Xenon gas for inhalation; MNK-6105, an ammonia scavenger for the treatment of hepatic encephalopathy, a neuropsychiatric syndrome associated with hyperammonemia; VTS-270 that is in Phase III development for Niemann-Pick Type C, a neurodegenerative fatal disease; and CPP-1X/sulindac, which is in Phase III development for Familial Adenomatous Polyposis. Mallinckrodt public limited company markets its branded products to physicians, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. The company is based in Staines-Upon-Thames, the United Kingdom.
The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Mallinckrodt (MNK) Presents At 43rd Annual Healthcare Conference - Slideshow

2023-03-23
The following slide deck was published by Mallinckrodt plc in conjunction with this event.

Mallinckrodt to Present New Retrospective Data on Effect of Acthar® Gel (Repository Corticotropin Injection) to Reduce Corticosteroid Use and Burden for Advanced Sarcoidosis at the Academy of Managed Care Pharmacy (AMCP) 2023 Annual Meeting

2023-03-21
Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that an abstract highlighting results from a retrospective analysis evaluating the corticosteroid-sparing effect and reduction of corticosteroid burden of Acthar® Gel (repository corticotropin injection) therapy in patients with advanced sarcoidosis,1 has been selected for a poster presentation at the Academy of Managed Care Pharmacy (AMCP) 2023 Annual Meeting taking place in San Antonio, Texas from

CORRECTING and REPLACING Buxton Helmsley Issues Letter to U.S. Senators Warren and Whitehouse Related to Mallinckrodt Plc. $2B Concealment of Asset Value Depreciation Expenses

2023-03-17
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Buxton Helmsley Issues Letter to U.S. Senators Warren and Whitehouse Related to Mallinckrodt Plc. $2B Concealment of Asset Value Depreciation Expenses

2023-03-17
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

CORRECTING and REPLACING Buxton Helmsley Issues Letter to Mallinckrodt Plc. Regarding $2B Concealment of Asset Value Depreciation Expenses, Releases Full Analysis to the SEC and U.S. Senate Finance Committee

2023-03-17
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Silence Therapeutics: Breaking The Silence On An Under-The-Radar Mid-Stage SiRNA Platform

2023-03-13
Silence Therapeutics is an underfollowed British siRNA company focusing on cardiovascular and autoimmune diseases. Read why we rate SLN stock a speculative Buy.

McKinsey Consulted VA While Advising Opioid Makers to Target Agency for Sales

2023-03-13
Since at least 2009, McKinsey has been a consultant to the U.S. Department of Veterans Affairs. During part of that time, the consulting giant also advised some of the world’s biggest opioid producers to target the federal agency for sales of their products, according to newly released documents.

Mallinckrodt plc (AMEX:MNK) Q4 2022 Earnings Call Transcript

2023-03-10
Mallinckrodt plc (AMEX:MNK) Q4 2022 Earnings Call Transcript February 28, 2023 Operator: Good day, and thank you for standing by. Welcome to the Mallinckrodt Q4 2022 Earnings Announcement. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. please be advised that today’s conference is […]

Mallinckrodt Announces Reimbursement Approval in Japan for the CELLEX® Extracorporeal Photopheresis (ECP) System for the Treatment of Chronic Graft Versus Host Disease (cGvHD)

2023-03-08
Mallinckrodt plc, (NYSE American: MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that Japan's National Health Insurance (NHI) system has approved reimbursement for the CELLEX® extracorporeal photopheresis (ECP) system for the treatment of steroid-resistant or -intolerant chronic graft versus host disease (cGvHD).

ANI Pharma draws Buy at Guggenheim on potential of autoimmune therapy

2023-03-01
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.